Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830046 · ClinicalTrials.gov registry record
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
A clinical trial of Multiple Myeloma and Covid19, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 146
- Enrollment target
- 2
- Study locations
NCT04830046 is a study of Multiple Myeloma and Covid19 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 146 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04830046, a study of Multiple Myeloma and Covid19, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
Conditions Studied
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-09-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04830046
The ClinicalTrials.gov registry entry for NCT04830046 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT04830046 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04830046 about?
NCT04830046 is a clinical study titled "Covid-19 Vaccine Responsiveness in MM and Waldenstrom". This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
What is the current status of trial NCT04830046?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2021-04-15. Estimated completion is 2022-09-14.
What conditions does trial NCT04830046 study?
This clinical trial studies the following conditions: Multiple Myeloma, Covid19, Waldenstrom Macroglobulinemia, Immune System Disorder.
Who is sponsoring clinical trial NCT04830046?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04830046 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.